Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat

Certara (Nasdaq: CERT) agreed to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, with closing expected in Q2 2026 subject to customary conditions.

Rhea-AI Summary

Certara (Nasdaq: CERT) agreed to sell its Regulatory and Medical Writing business to Veristat for up to $135 million, with closing expected in Q2 2026 subject to customary conditions.

In 2025 the unit generated $50 million revenue and $17 million adjusted EBITDA and includes ~220 employees. Certara will update 2026 guidance upon close and intends to deploy proceeds to advance its MIDD and Clinical Intelligence strategy.

Positive

• Deal value up to $135 million
• 2025 revenue contribution: $50 million
• 2025 adjusted EBITDA contribution: $17 million
• 220 employees included in the business transfer
• Proceeds earmarked to accelerate MIDD and Clinical Intelligence

Negative

• Divestiture removes ~$50 million of annual revenue
• Certara will revise 2026 guidance after transaction close
• Transaction completion is subject to customary closing conditions

Argus Apr 22 session

+2.90% close to close Open Argus

Details

News Market Reaction – CERT

On Apr 22, the day this news came out, CERT closed 2.90% above the previous close.

Data tracked by StockTitan Argus for the Apr 22 session.

Key Figures

Transaction consideration: $135 million Segment revenue: $50 million Segment adjusted EBITDA: $17 million +1 more

Transaction consideration

$135 million

Maximum consideration for sale of Regulatory and Medical Writing business

Segment revenue

$50 million

2025 revenue from Regulatory and Medical Writing business

Segment adjusted EBITDA

$17 million

2025 adjusted EBITDA from Regulatory and Medical Writing business

Employees divested

220 employees

Headcount in Regulatory and Medical Writing business being sold

Historical Context

5 past events · Latest: Apr 09

5 events

1. Apr 09

   Earnings date notice

   24h Move

   +2.6%

   Announcement of Q1 2026 earnings release date and conference call details.

2. Mar 03

   Regulatory acceptance

   24h Move

   +2.7%

   FDA acceptance of Simcyp PBPK modeling in place of multiple clinical pharmacology trials.

3. Feb 27

   Investor conferences

   24h Move

   +4.1%

   Management participation in several March 2026 investor conferences with webcasts.

4. Feb 26

   Earnings and guidance

   24h Move

   +3.2%

   FY2025 growth, Q4 results, new CEO, and full-year 2026 guidance ranges provided.

5. Jan 29

   Earnings date notice

   24h Move

   -1.5%

   Notification of Q4 and FY2025 earnings release timing and call logistics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

model-informed drug development (midd), adjusted ebidta

2 terms

model-informed drug development (midd) medical

"Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence"

Model-informed drug development uses computer-based math models and simulations of how a drug behaves in the body and how patients respond to guide decisions across research and clinical trials. Like a flight simulator for drug programs, it helps teams test scenarios, pick better doses, design smarter trials and reduce surprises, which can lower costs, shorten timelines and de-risk programs—information investors use to judge a drug’s chances and capital efficiency.

adjusted ebidta financial

"generated $50 million in revenue and $17 million in adjusted EBITDA, excluding unallocated"

Adjusted EBITDA is a company’s reported profit from its core operations before subtracting interest, taxes, and accounting for long-term costs like depreciation, further cleaned up by removing one-time, unusual, or non-cash items. Think of it as the operating cash-flow picture after erasing temporary blips so different periods and companies can be compared more easily; investors use it to judge underlying business performance, but it is not a standardized accounting measure and can be shaped by management choices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Transaction sharpens focus on Model-Informed Drug Development (MIDD) and Clinical Intelligence 

Updated 2026 guidance to be provided upon transaction close

RADNOR, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it has entered into a definitive agreement to sell its Regulatory and Medical Writing business to Veristat for a consideration of up to $135 million. The transaction is expected to close during the second quarter of 2026 subject to customary closing conditions.

“Certara’s strategy is centered on expanding the scale, reach, and impact of our MIDD and Clinical Intelligence solutions,” said Jon Resnick, Chief Executive Officer. “This transaction underlines our commitment to the acceleration of AI-integrated modeling and simulation across the drug development lifecycle.”

In 2025, the Regulatory and Medical Writing business generated $50 million in revenue and $17 million in adjusted EBITDA, excluding unallocated overhead expense. The Regulatory and Medical Writing business includes approximately 220 employees.

“This transaction enhances our ability to accelerate investment in Certara’s integrated MIDD platform for customers, while sharpening our focus on product innovation and operational excellence,” said Resnick. “Consistent with our strategy, we intend to deploy the proceeds to drive long-term value for customers, patients, and shareholders.”

Certara plans to update its 2026 guidance to reflect the sale of the Regulatory and Medical Writing business upon transaction close.

Perella Weinberg Partners LP served as the financial advisor, and Troutman Pepper Locke LLP served as legal counsel to Certara. Guggenheim Securities, LLC served as the financial advisor, and McDermott Will & Schulte served as legal counsel to Veristat.

About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Visit us at www.certara.com.

Forward-Looking Statements
This press release contains certain statements that constitute forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the company’s plans to sell its Regulatory and Medical Writing business, the expected timetable for completing the transaction, the expected use of proceeds from the transaction and the future financial and operating performance of the company following the transaction. Actual results could differ materially from those in the forward-looking statements due to, among other things, the possibility that the transaction does not close; unanticipated costs and length of time required to comply with legal requirements and regulatory approvals applicable to the transaction; customer and shareholder reaction to the transaction; disruption from the transaction making it more difficult to maintain business and operational relationships; significant transaction costs; changes in general and international economic conditions; and the other factors detailed under the captions “Risk Factors” and “Special Note Regarding Forward-Looking Statements” and elsewhere in our Securities and Exchange Commission (“SEC”) filings, and reports, including the Form 10-K filed by the company with the Securities and Exchange Commission on February 26, 2026, and subsequent reports filed with the SEC. Any forward-looking statements speak only as of the date of this release and, except to the extent required by applicable securities laws, we expressly disclaim any obligation to update or revise any of them to reflect actual results, any changes in expectations or any change in events.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Alyssa Horowitz
Pan Communications
certara@pancomm.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the value and timing of Certara's (CERT) sale of its Regulatory and Medical Writing business?

Certara agreed to sell the unit to Veristat for up to $135 million. According to the company, the transaction is expected to close in Q2 2026, subject to customary closing conditions and adjustments.

How much revenue and EBITDA did the sold Certara (CERT) business generate in 2025?

The Regulatory and Medical Writing business generated $50 million revenue and $17 million adjusted EBITDA in 2025. According to the company, those figures exclude unallocated overhead expense.

Will Certara (CERT) update its 2026 guidance because of the sale?

Yes. According to the company, Certara plans to update its 2026 guidance to reflect the sale upon transaction close, with specific revised guidance to be provided after closing.

How many employees are included in the Certara (CERT) Regulatory and Medical Writing sale to Veristat?

The transaction covers approximately 220 employees. According to the company, those employees are part of the Regulatory and Medical Writing business being transferred to Veristat.

How does Certara (CERT) plan to use proceeds from the sale to Veristat?

Certara intends to deploy proceeds to advance its MIDD and Clinical Intelligence platform and product innovation. According to the company, funds will support long-term value for customers and shareholders.